Butenafine hydrochloride is chemically known as N-4-tertbutylbenzyl-N-methyl-1-naphthalenemethylamine hydrochloride. Butenafine, a benzylamine derivative, is a new generation antimycotic compound. It is easily soluble in methanol, ethanol, dichloromethane, and chloroform, but not in water. The allyl radical in butenafine hydrochloride is substituted by a butylbenzyl group.

Butenafine hydrochloride has been used as a standard in high-performance liquid chromatography (HPLC) method to determine butenafine hydrochloride in butenafine-loaded nanosponges.

Butenafine exhibits fungicidal and antimycotic activity. This fungal squalene epoxidase inhibitor serves as an effective fungicide against T. rubrum, T. mentagrophytes, Microsporum canis, Aspergillus fumigatus, Sporothrix schenckii, Candida parapsilosis, and C. albicans. It is considered more effective and rapid than other antifungal drugs at curing dermatophytosis and preventing recurrences. In humans, it is used topically to treat tinea conditions and superficial candidiasis. Butenafine is considered a promising antimycotic compound to treat tinea pedis due to its efficiency, safety profile, relapse rates, and cost-effectiveness.

Butenafine is an antifungal; squalene epoxidase inhibitor. It inhibits the synthesis of ergosterol needed in fungal cell membranes.

Butenafine possesses antifungal property. It is a squalene epoxidase inhibitor. Butenafine can inhibit the synthesis of ergosterol needed in fungal cell membranes.

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.